Penumbra (PEN) FCF Margin Growth (3y) (2017 - 2026)
Penumbra (PEN) FCF Margin Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 38.00 |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 30.00 |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -310.00 |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 96.00 |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -2,196.00 |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 2,679.00 |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -20.00 |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -472.00 |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Penumbra | 12.48 Bn | 11.87 Bn | 253.41 Mn | 1,536.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,536.00 |
| Dec 31, 2025 | 1,479.00 |
| Sep 30, 2025 | 3,319.00 |
| Jun 30, 2025 | 2,631.00 |
| Mar 31, 2025 | 1,922.00 |
| Dec 31, 2024 | 2,705.00 |
| Sep 30, 2024 | -86.00 |
| Jun 30, 2024 | 688.00 |
| Mar 31, 2024 | 2,250.00 |
| Dec 31, 2023 | 1,395.00 |
| Sep 30, 2023 | 366.00 |
| Jun 30, 2023 | 3,369.00 |
| Mar 31, 2023 | 1,639.00 |
| Dec 31, 2022 | 338.00 |
| Sep 30, 2022 | -2,717.00 |
| Jun 30, 2022 | -1,855.00 |
| Mar 31, 2022 | -237.00 |
| Dec 31, 2021 | -1,907.00 |
| Sep 30, 2021 | 513.00 |
| Jun 30, 2021 | 112.00 |